PMLiVE11h
NHS England begins newborn screening programme to identify rare genetic conditions
NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...
PMLiVE6d
Quality in Care (QiC) Dermatology 2025
The fourth annual QiC Dermatology Awards took place in Reading earlier this month and results can be found online here: QiC ...
PMLiVE7d
Teeing Off with the Masters: Lessons for Brands Inspired by Golf’s Biggest Event
Highly encouraged to read this in Jim Nantz voice Hello friends. Consider a brand. Picture an experience. The Masters, one of ...
PMLiVE9d
Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment
Astellas Pharma’s claudin 18.2-directed cytolytic antibody has been approved by the European Commission (EC) as part of a first-line combination treatment for a subset of gastric cancer patients.
PMLiVE10d
Embracing risk: it’s time for big thinking in neurodegeneration
Risk taking is complicated. In business, ebullient entrepreneurs are lauded for putting their livelihood on the line and taking risks, while serial gamblers who do the same are frowned upon. When it ...
PMLiVE10d
Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients
Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s human medicines committee to treat younger eosinophilic oesophagitis (EoE) patients. The Committee ...
PMLiVE7d
AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer
AstraZeneca’s (AZ) Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer patients. The epidermal growth factor receptor ...
PMLiVE10d
Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults
Ipsen’s Iqirvo (elafibranor) has been conditionally approved by the European Commission (EC) to treat primary biliary cholangitis (PBC). The oral peroxisome proliferator-activated receptor (PPAR) ...
PMLiVE9d
Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation
Pfizer and BioNTech’s updated COVID-19 vaccine targeting the KP.2 strain, a descendant of JN.1, has been recommended by the European Medicines Agency’s human medicines committee for use in individuals ...
PMLiVE11d
EC approves Bavarian Nordic’s mpox vaccine Imvanex for use in adolescents
The European Commission (EC) has extended the marketing authorisation for Bavarian Nordic’s smallpox and mpox vaccine to include adolescents aged 12 to 17 years. Imvanex (MVA-BN) is already approved ...
PMLiVE11d
Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS
Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). The ...
PMLiVE9d
FDA approves Zevra’s Miplyffa as first drug for Niemann-Pick disease type C
The US Food and Drug Administration (FDA) has approved Zevra Therapeutics’ Miplyffa (arimoclomol) to treat Niemann-Pick disease type C (NPC), an ultra-rare lysosomal storage disorder affecting one in ...